Interview with Verantos CEO Dan Riskin

Real world evidence or RWE is a promising way to answer questions about how therapies perform, going beyond the controlled confines of randomized clinical trials with narrow patient populations to analyze what happens in the so-called real world. But the first generation of RWE hasn’t always lived up to its promise. It is often incomplete, inaccurate or just not fit for purpose.

My guest, Dan Riskin is CEO of Verantos. The company focuses on providing high-validity real-world evidence at scale, to realize the promise of RWE.

Health Business Group is a boutique healthcare consulting firm that develops growth strategies for companies like Verantos. Contact us to learn more.

Previous
Previous

Interview with CalmWave CEO Ophir Ronen

Next
Next

Interview with Arrive Health CEO Kyle Kiser